Knight Therapeutics (GUD.TO) has launched Tavalisse, its treatment for adult patients with chronic immune thrombocytopenia (ITP) in Mexico, the company said overnight Wednesday.
Tavalisse is indicated for patients who have had an insufficient response to a previous treatment.
Knight announced its agreement with Rigel Pharmaceuticals, in May 2022, securing exclusive rights to commercialize Tavalisse in Latin America.
"The launch of Tavalisse in Mexico represents an important milestone in our mission to transform lives by expanding access to innovative therapies for patients across Latin America," said Samira Sakhia, chief executive of Knight Therapeutics. "Chronic ITP continues to pose significant challenges for many patients, and we are proud to introduce a differentiated therapeutic treatment option for those who have not benefited from existing therapies. This milestone reflects our ongoing commitment to strengthening our presence in the region and providing meaningful solutions to the patients and physicians who need them."
Knight Therapeutic shares closed down $0.11, to $8.05 on Wednesday on the Toronto Stock Exchange.